Cited 7 times in
Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강석민 | - |
dc.date.accessioned | 2022-09-14T01:51:33Z | - |
dc.date.available | 2022-09-14T01:51:33Z | - |
dc.date.issued | 2021-12 | - |
dc.identifier.issn | 2211-9132 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190644 | - |
dc.description.abstract | Despite significant advances in the management of heart failure with reduced ejection fraction (HFrEF), there remains an enormous health problem with high morbidity and mortality over the last few decades. The neprilysin inhibitor enhances the activity of natriuretic peptides, producing vasodilation, natriuresis, and diuresis. Angiotensin receptor blockers inhibit the renin-angiotensin-aldosterone system. Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to improve cardiovascular outcomes in HFrEF and delay the progression of chronic kidney disease (CKD) in patients with HFrEF. The PARADIGM-HF study showed a reduction in diuretic need in the ARNI group. While the use of diuretics is effective in volume control in patients with HFrEF, their use has the potential to adversely affect renal function. Therefore, ARNI therapy could benefit patients with heart failure and CKD by reducing cardiovascular morbidity and mortality and possibly retarding the progression of CKD, although more clinical evidence is required in patients with severe CKD and end-stage renal disease. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Elsevier Korea | - |
dc.relation.isPartOf | KIDNEY RESEARCH AND CLINICAL PRACTICE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | In-Jeong Cho | - |
dc.contributor.googleauthor | Seok-Min Kang | - |
dc.identifier.doi | 10.23876/j.krcp.21.900 | - |
dc.contributor.localId | A00037 | - |
dc.relation.journalcode | J01942 | - |
dc.identifier.eissn | 2211-9140 | - |
dc.identifier.pmid | 34922429 | - |
dc.subject.keyword | Chronic kidney disease | - |
dc.subject.keyword | Heart failure | - |
dc.subject.keyword | Neprilysin | - |
dc.subject.keyword | Renin-angiotensin-aldosterone system | - |
dc.contributor.alternativeName | Kang, Seok Min | - |
dc.contributor.affiliatedAuthor | 강석민 | - |
dc.citation.volume | 40 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 555 | - |
dc.citation.endPage | 565 | - |
dc.identifier.bibliographicCitation | KIDNEY RESEARCH AND CLINICAL PRACTICE, Vol.40(4) : 555-565, 2021-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.